Drugs & Aging

, Volume 29, Issue 3, pp 1–1

Erratum to: Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer

  • Lesley J. Scott
  • Lily P. H. Yang
  • Katherine A. Lyseng-Williamson
Erratum

DOI: 10.2165/11632600-000000000-00000

Cite this article as:
Scott, L.J., Yang, L.P.H. & Lyseng-Williamson, K.A. Drugs Aging (2012) 29: 1. doi:10.2165/11632600-000000000-00000

Article Corrected

Scott LJ, Yang LPH, Lyseng-Williamson KA. Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer. Drugs Aging 2012; 29 (3): 243–8

Correction Made

Page 244, table I, ‘Clinical benefitssubsection: The third sentence, which previously read:

“Only second-line therapy available that prolongs overall survival” has now been corrected as follows:

“Only second-line hormonal therapy currently shown to prolong overall survival”

Note

All online versions of this article have been updated to reflect this correction.

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Lesley J. Scott
  • Lily P. H. Yang
  • Katherine A. Lyseng-Williamson

There are no affiliations available